周一盘中，诺瓦瓦克斯医药（NVAX）股价大幅下跌5.02%，引发市场关注。这一跌势与美国食品药品监督管理局（FDA）一位具有争议性的官员重返岗位的消息密切相关。
据报道，此前被解职的FDA疫苗监管官员Vinay Prasad将重新执掌生物制品评价与研究中心。Prasad曾因多项决策引发争议，其中包括限制诺瓦瓦克斯医药和Moderna新冠疫苗的使用范围，这一决定当时引起了公共卫生专家的强烈不满。
Prasad的回归引发了生物科技板块的普遍抛售。投资者担心，他的重新上任可能会对包括诺瓦瓦克斯医药在内的生物科技公司的产品审批和监管政策产生重大影响。这一消息不仅影响了诺瓦瓦克斯医药，还导致多家生物科技公司股价在盘前出现下跌，反映了市场对行业前景的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.